KVUE
Kenvue
$19.21
▲ 0.2%Updated Aug 7, 11:30 AM ET
KVUE at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 55/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 15.2% over the last 12 months
Market Cap
$38.07B
P/E
22.52x
Forward P/E (est.)
16.08x
ROE
15.2%
Revenue Growth
-0.1%
EPS Growth
53.7%
Profit Margin
10.6%
FCF Yield
—
Debt / Equity
0.79x
ROIC
10.0%
Interest Coverage
—
Current Ratio
0.98x
Dividend Yield
4.5%
Implied Growth (rev. DCF)
4.3%
Rating Score
55/100
Kenvue (KVUE) is a large-cap company in the Personal Care Products industry, part of the Consumer Staples sector of the S&P 500, with a market value around $38.07B.
In its latest reported year it generated about $15.12B in revenue and $1.47B in net profit.
Our model rates KVUE Neutral (55/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what KVUE's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. KVUE trades near $19.21, above its 50-day average ($17.78) and 200-day average ($17.27). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 77 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. KVUE's is $0.37 (~1.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month KVUE found buyers near $16.67 (support) and sellers near $19.87 (resistance); its 52-week range is $14.02–$22.87. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.5× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
3Y CAGR
0.2%
Revenue moved from $15.05B in 2022 to $15.12B in 2025, a 0.2% compound annual growth rate. The most recent year declined 0.1% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
58.1%
Operating Margin
16.0%
Net Margin
9.7%
ROE
15.2%
Kenvue keeps about 10.6% of each sales dollar as net profit, with a 58.1% gross margin and 16.0% operating margin. Return on equity is 15.2% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$7.69B
Net Debt
$6.61B
Net Debt / EBITDA
2.74x
Debt / Equity
0.79x
Leverage: debt-to-equity is 0.8x, with a current ratio of 1.0x. That is a moderate, manageable debt load for most businesses. It carries roughly $7.69B of total debt against $1.07B of cash.
Operating CF
$2.20B
Free Cash Flow
$1.72B
FCF Margin
11.4%
In the latest year Kenvue produced about $2.20B of operating cash flow and $1.72B of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
Coverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.
Dividend yield
4.5%
Per share (latest FY)
$0.82
Total paid (latest FY)
$1.58B
History on record
3 years
dividend uses 92% of free cash flow
108% of net income paid out
total dividends increased 2 years in a row
no cuts in the last 3 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
22.52x
P/S
2.32x
P/B
3.19x
EV / EBITDA
—
KVUE trades at 22.5x trailing earnings (about 16.1x on estimated forward earnings), 2.3x sales, and 3.2x book value. Reverse-engineering today's price implies the market expects roughly 4.3% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$12.22
Current price
$19.21
Starting FCF (latest 10-K)
$1.72B
Growth, years 1–5
-0.1%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where KVUE sits versus its Consumer Staples sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 48 Consumer Staples companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How KVUE stacks up against its Consumer Staples peers — valuation, profitability, and growth versus the sector median.
In the Consumer Staples sector (74 S&P 500 companies), KVUE ranks #16 of 74 by our overall rating. It trades at roughly in line versus the sector on earnings (22.5x P/E vs. 22x median) with a lower return on equity (15.2% vs. 18.1%) and slower revenue growth (-0.1% vs. 3.4%).
P/E vs sector
22.5x
median 22x
ROE vs sector
15.2%
median 18.1%
Growth vs sector
-0.1%
median 3.4%
Sector rank
#16
of 74 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Consumer Staples companies by sub-industry and size. Sector median is across all 74 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $19.21 today · expected CAGR -8% – 1%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $15.58B | $16.05B | $16.53B | $17.02B | $17.53B |
| Net income | $1.56B | $1.60B | $1.65B | $1.70B | $1.75B |
| EPS | $0.79 | $0.81 | $0.83 | $0.86 | $0.88 |
| Share price (low) | $11.00 | $11.33 | $11.67 | $12.02 | $12.38 |
| Share price (high) | $18.08 | $18.62 | $19.18 | $19.75 | $20.35 |
| CAGR (low–high) | -43% / -6% | -23% / -2% | -15% / -0% | -11% / 1% | -8% / 1% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for KVUE:
- Strong return on equity (15.2%) shows capital is put to work well.
- Pays a 4.5% dividend on top of any price gains.
The case against KVUE:
- Revenue growth is slow/negative (-0.1%), limiting the upside engine.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Growth risk — sluggish revenue (-0.1%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Kenvue is a large-cap consumer staples business with shrinking revenue, with modest profitability, and a heavier debt load to watch. It trades at 22.5x earnings, which our model scores Neutral (55/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 20 Wall Street analysts covering KVUE recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+25 pts of buy ratings).
Latest SEC Filings
KVUE's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
KVUE — frequently asked questions
Is KVUE a good stock to buy?
We don't give buy or sell advice. Our model rates Kenvue Neutral (55/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is KVUE's rating on The Stocks School?
Kenvue currently scores 55/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does KVUE's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Kenvue's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for KVUE calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this KVUE analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell KVUE. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.